TABLE 2.

Univariate and Multivariate Associations with Early (One Year) Mortality by Cox Proportional Hazards Model

	Univariate Modelsa			Adjusted Modelsb
	HR	(95% CI)	P	HR	(95% CI)	P
Cumulative doses of chemotherapy w/in 105 days, n = 160	0.94	(0.77, 1.13)	0.49	0.96	(0.79, 1.18)	0.72
Age (year)	0.99	(0.98, 1.00)	0.18
Gender, n = 160:
Female		Reference			Reference
Male	0.67	(0.41, 1.12)	0.12	0.58	(0.34, 1.01)	0.053
BMI (among those 18 years or older), n = 107
<18.5		Reference
>18.5	0.70	(0.36, 1.36)	0.29
Tumor Stage, n = 160:
I		Reference
II	1.32	(0.18, 9.45)	0.78
III	1.25	(0.28, 5.55)	0.77
IV	1.55	(0.36, 6.64)	0.55
Unknown	2.17	(0.50, 9.41)	0.30
Tumor Stage, n = 160:
I & II		Reference
III & IV	1.25	(0.44, 3.52)	0.67
Unknown	1.91	(0.65, 5.62)	0.24
Preexisting HIV WHO staging illness* (among HIV+ participants), n = 40:
I & II		Reference
III & IV	0.29	(0.10, 0.88)	0.029
Unknown	0.77	(0.23, 2.55)	0.67
HIV Category, n = 154
Negative		Reference			Reference
Positive, no ARV treatment	5.37	(2.30, 12.53)	<0.001	8.99	(3.62, 22.34)	<0.001
Positive, any ARV	1.04	(0.56, 1.96)	0.89	1.14	(0.57, 2.30)	0.71
Unknown	2.25	(0.98, 5.13)	0.055	2.04	(0.82, 5.04)	0.12
Hemoglobin (g/dl) n = 152	0.89	(0.82, 0.97)	0.005	0.88	(0.80, 0.97)	0.008
LDH, n = 100
<300		Reference
≥300	0.95	(0.47, 1.91)	0.88
CD4 Count (cells/uL) (among HIV+ participants), n = 37
≤200		Reference
>200	0.62	(0.21, 1.87)	0.40
B-Symptoms, n = 160	1.99	(0.98, 4.05)	0.056	2.08	(1.00, 4.31)	0.050

BMI, body mass index categorized according to WHO⁴⁴,⁴⁵; WHO, World Health Organization; HIV, human immunodeficiency virus; LDH, lactate dehydrogenase; ARV, Antiretroviral.

^*had or had had another WHO stage-defining illness NHL diagnosis

^a= Number of observations in each the bivariate model are indicated by the different numbers, n

^b(146) = No. of observations used in the multivariate model.